Immune Design Corp. (IMDZ) Receives Daily News Impact Score of 0.16
News stories about Immune Design Corp. (NASDAQ:IMDZ) have trended somewhat positive on Thursday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immune Design Corp. earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8784587038815 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s rankings:
- Relative Strength Alert For Immune Design (thestreet.com)
- Immune Design continues freefall, down 20% (seekingalpha.com)
- Immune Design Corp. (IMDZ) Downgraded by Wells Fargo & Company (americanbankingnews.com)
- Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients (finance.yahoo.com)
Immune Design Corp. (IMDZ) traded down 4.1802% during midday trading on Thursday, reaching $6.2762. 237,038 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $10.27 and its 200 day moving average is $8.60. Immune Design Corp. has a 52 week low of $4.50 and a 52 week high of $13.05. The firm’s market capitalization is $160.79 million.
Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. On average, equities analysts anticipate that Immune Design Corp. will post ($2.29) earnings per share for the current year.
A number of equities research analysts have commented on the stock. Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $29.00 to $10.00 in a research note on Tuesday. ValuEngine cut shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price on the stock. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.75.
ILLEGAL ACTIVITY NOTICE: “Immune Design Corp. (IMDZ) Receives Daily News Impact Score of 0.16” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/10/19/immune-design-corp-imdz-receives-daily-news-impact-score-of-0-16.html.
In other Immune Design Corp. news, insider Wayne Gombotz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total value of $114,300.00. Following the completion of the transaction, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.70% of the company’s stock.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.